TNFSF13B and systemic lupus erythematosus: Belimumab, a monoclonal antibody (mAb) targeted against the B cell activating factor (BAFF) [8], was approved in the USA in 2011 for active SLE [9] and lupus nephritis [10], but uptake has been low in many care settings including in the USA [11].